Peroxisome Proliferator-Activated Receptors: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 52: | Line 52: | ||
==Additional 3D Structures of PPAR== | ==Additional 3D Structures of PPAR== | ||
'' | ''Updated December 2011'' | ||
===PPARα Structures=== | |||
[[1k7l]] – hPPARα LBD + G2409544 + SRC-1<br /> | |||
[[3e94]] – hPPARα LBD + tributyltin <br /> | |||
[[1i7g]] – hPPARα LBD + AZ242<br /> | |||
[[1kkq]] – hPPARα LBD + GW6471 Antagonist + SMRT<br /> | |||
[[2npa]] - hPPARα LBD+ propanoic acid derivative + SRC-1<br /> | |||
[[2p54]] - hPPARα LBD + SRC-1<br /> | |||
[[2rew]] - hPPARα LBD + azetidinone derivative activator<br /> | |||
[[2znn]], [[2zno]], [[2znp]], [[2znq]], [[3kdu]] - hPPARα LBD+ agonist<br /> | |||
[[3fei]], [[3fej]], [[3g8i]], [[3sp6]] - hPPARα LBD+ agonist + SRC-1<br /> | |||
[[3et1]] - hPPARα LBD + SRC-1 + indole derivative | |||
===PPARγ Structures=== | ===PPARγ Structures=== | ||
[[3prg]], [[2qmv]], [[1prg]] – hPPARγ LBD<br /> | |||
[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]] – hPPARγ LBD + ligand - human<br /> | [[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]] – hPPARγ LBD + ligand - human<br /> | ||
[[2prg]], [[1fm6]] – hPPARγ LBD + Rosiglitazone + SRC-1 <br /> | [[2prg]], [[1fm6]] – hPPARγ LBD + Rosiglitazone + SRC-1 <br /> | ||
[[ | [[2xkw]] - hPPARγ LBD+ pioglitazone<br /> | ||
[[3b0q]] - hPPARγ LBD+ netoglitazone derivative<br /> | |||
[[4prg]] – hPPARγ LBD + 2,4-thiazolidinedione deriveative <br /> | [[4prg]] – hPPARγ LBD + 2,4-thiazolidinedione deriveative <br /> | ||
[[1fm9]] – hPPARγ LBD + GI262570, Farglitazar + SRC-1<br /> | [[1fm9]] – hPPARγ LBD + GI262570, Farglitazar + SRC-1<br /> | ||
| Line 70: | Line 86: | ||
[[1rdt]] – hPPARγ LBD + GI262570, Fraglitazar + CBP<br /> | [[1rdt]] – hPPARγ LBD + GI262570, Fraglitazar + CBP<br /> | ||
[[1zgy]] – hPPARγ LBD + Rosaglitazone + SHP<br /> | [[1zgy]] – hPPARγ LBD + Rosaglitazone + SHP<br /> | ||
[[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]] – hPPARγ LBD+ agonists <br /> | [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]] – hPPARγ LBD+ agonists <br /> | ||
[[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]] - hPPARγ LBD+ partial agonists<br /> | [[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]] - hPPARγ LBD+ partial agonists<br /> | ||
[[3lmp]] – hPPARγ LBD + a cercosporamide derivative modulator<br /> | [[3lmp]] – hPPARγ LBD + a cercosporamide derivative modulator<br /> | ||
[[3b1m]] - hPPARγ LBD+ cercosporamide derivative modulator + SRC-1<br /> | |||
[[2gtk]] - hPPARγ LBD+ SRC-1 decamer<br /> | [[2gtk]] - hPPARγ LBD+ SRC-1 decamer<br /> | ||
[[2om9]] - hPPARγ LBD + ajulemic acid<br /> | [[2om9]] - hPPARγ LBD + ajulemic acid<br /> | ||
[[2q6s]] - hPPARγ LBD + benzoic acid derivative<br /> | [[2q6s]], [[3b0r]] - hPPARγ LBD + benzoic acid derivative<br /> | ||
[[3osi]], [[3osw]] - hPPARγ LBD + bisphenol derivative<br /> | [[3osi]], [[3osw]], [[3pba]] - hPPARγ LBD + bisphenol derivative<br /> | ||
[[2p4y]], [[3adt]], [[3adu]], [[3adw]], [[3et3]], [[2hfp]] - hPPARγ LBD+ indole modulator<br /> | [[2p4y]], [[3adt]], [[3adu]], [[3adw]], [[3et3]], [[2hfp]] - hPPARγ LBD+ indole modulator<br /> | ||
[[2pob]] - hPPARγ LBD + fraglitazar analogue<br /> | [[2pob]] - hPPARγ LBD + fraglitazar analogue<br /> | ||
| Line 83: | Line 100: | ||
[[3ads]], [[3adx]] - hPPARγ LBD + indomethacin<br /> | [[3ads]], [[3adx]] - hPPARγ LBD + indomethacin<br /> | ||
[[3adv]] - hPPARγ LBD + serotonin<br /> | [[3adv]] - hPPARγ LBD + serotonin<br /> | ||
[[3cs8]] - hPPARγ LBD + PGC-1A<br /> | [[3cs8]], [[3u9q]]- hPPARγ LBD + PGC-1A<br /> | ||
[[3cwd]] - hPPARγ LBD + SRC1-2<br /> | [[3cwd]] - hPPARγ LBD + SRC1-2<br /> | ||
[[3fur]], [[3kmg]] - hPPARγ LBD + SRC-1+ modulator<br /> | [[3fur]], [[3kmg]] - hPPARγ LBD + SRC-1+ modulator<br /> | ||
[[3k8s]] - hPPARγ LBD + antidiabetic agent<br /> | [[3k8s]] - hPPARγ LBD + antidiabetic agent<br /> | ||
[[3h0a]] - hPPARγ LBD + SRC 1 + retinoic acid receptor α + retinoic acid + partial agonist<br /> | [[3h0a]] - hPPARγ LBD + SRC 1 + retinoic acid receptor α + retinoic acid + partial agonist<br /> | ||
===PPARδ Structures=== | ===PPARδ Structures=== | ||
| Line 110: | Line 115: | ||
[[3et2]] – PPARδ + 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid<br /> | [[3et2]] – PPARδ + 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid<br /> | ||
[[2env]] – hPPARδ zinc finger domain<br /> | [[2env]] – hPPARδ zinc finger domain<br /> | ||
[[2j14]], [[2xyj]], [[2xyw]], [[2xyx]], [[3oz0]] - hPPARδ LBD + agonist<br /> | [[2j14]], [[2xyj]], [[2xyw]], [[2xyx]], [[3oz0]], [[3sp9]] - hPPARδ LBD + agonist<br /> | ||
[[3peq]] - hPPARδ LBD + partial agonist<br /> | |||
[[3d5f]] - hPPARδ LBD +phenoxy derivative | [[3d5f]] - hPPARδ LBD +phenoxy derivative | ||